Canopy Growth (TSX:WEED) Stock Soars 6% on Strong Q3 Earnings Report

Canopy Growth (TSX:WEED)(NYSE:CGC) stock soared almost 6% after the pot company reported better-than-expected financial results.

| More on:

Canopy Growth (TSX:WEED)(NYSE:CGC), the world’s largest pot producer, reported its third-quarter results on Tuesday, which beat estimates. Canopy expects to turn a profit in the second half of 2022 after aggressive cost cuts and increased demand for cannabis products helped cut losses in the third trimester. The stock rose by almost 6% following the news.

Demand for cannabis products is rising

Since the start of last year, Canopy and rivals like Aphria and Aurora Cannabis have cut expenses by shutting down plants, cutting back on indoor growing, and laying off hundreds of employees.

Canopy is also placing its hopes on the large U.S. market, which is likely to open up, thanks to the favourable opinion of the Joe Biden administration on the cannabis industry.

Market conditions have also improved. As the pandemic shut down several businesses and economies, demand for cannabis products such as gelatin bears, brownies, and drinks, known for their links to relaxation, increased.

Canopy, which sells a line of products from dried flowers to chocolates and weed-mixed drinks, said its net sales rose 23% in the quarter to $152.5 million.

Its adjusted EBITDA loss fell from $97 million to $68.4 million in the third quarter, although asset impairments and one-time restructuring costs led the company to record a loss of $829.3 million, up from $109 million in the year-ago quarter. Expenses fell 15% to $144.1 million.

Analysts polled by Bloomberg had expected Canopy to report revenue of $147.6 million and an adjusted EBITDA loss of $71.1 million.

The cannabis company says the loss was $2.43 per diluted share for the quarter ended Dec. 31, compared to a loss of $109.6 million or $0.26 per share a year earlier.

According to Canopy, its last-quarter results included $416 million in impairment charges, restructuring, and other related charges, plus $291 million resulting from non-cash changes in fair value, mainly attributable to the higher share price of the company.

Canopy announced in December that it would shut down operations at five facilities across the country and lay off more than 200 workers in a bid to cut costs.

Net revenue for what was the company’s third quarter was $152.5 million, up from $123.8 million in the same quarter a year earlier.

Cannabis net revenue totaled $98.8 million, up from $90.4 million a year earlier, driven by an increase in Canadian recreational and international medical sales. Other revenues increased to $53.7 million from $33.4 million.

Canopy Growth expects to turn a profit in 2022

Canopy expects to achieve positive adjusted EBITDA in the second half of 2022 and an adjusted EBITDA margin of 20% for the full year 2024. It also expects positive operating cash flow for all of year 2023 and positive free cash flow for the whole of 2024. Projections are based on Canopy’s cost-reduction efforts and on the forecast of a compound annual growth in net sales of 40 at 50% between 2022 and 2024.

“We are executing against our cost savings program, with several initiatives already completed and more underway to build a leaner and more agile business,” Chief Financial Officer Mike Lee said in a statement.

Shares of Canopy Growth have almost doubled in value since the start of the year. With a price-to-sales (P/S) ratio of 43.6, the stock has become expensive. It might be best to wait for a pullback before buying shares.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »